Wednesday, September 10, 2014 10:05:06 PM
It is anticipated that preliminary human trials for the Vantage Health Sensor will begin next month at Scripps Translational Science Institute, paid for by a BioPharma partner of the Company. Mr. Barbera will continue to be Chairman and CEO of Nanobeak, which is the private company majority shareholder of Vantage Health
Read more: http://www.benzinga.com/pressreleases/14/07/b4738833/dr-kevin-buckman-named-chairman-and-ceo-of-vantage-health#ixzz3Cy6oxxxH
Recent VNTH News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:30:06 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM